30 closest matches · ranked by relevance
Multiple Sclerosis, Primary Progressive
Primary: Time to Onset of Clinical Disability Progression (CDP) Sustained for at Least 12 Weeks During the Double-Blind Treatment Period — NA; NA weeks
Primary Progressive Multiple Sclerosis
Primary: Change in the Area Under the Curve (AUC) of the Combinatorial Weight-Adjusted Disability Score (CombiWISE) From Baseline to Treatment Phase — -0.13; -1.04 units on a…
Multiple Sclerosis
Primary: Time to Confirmed Disease Progression (CDP) — NA; NA weeks — p=0.1442
Secondary Progressive Multiple Sclerosis
Primary: Effect on Cerebral Blood Flow in White Matter, Gray Matter, Deep White Matter, Deep Gray Matter, and Thalamus — 8.55; 5.12; 5.78; 2.06 Percentage of change in CBF
Multiple Sclerosis (MS)
Primary: Mean Overall Response Score (ORS) — -0.74; -0.75; -0.64 score on a scale
Multiple Sclerosis · Primary Progressive Multiple Sclerosis
Primary: Area Under the Curve (AUC) of the Combinatorial Weight-Adjusted Disability Score (CombiWISE) — 1.55; 0.80; 0.46; 0.89 units on a scale * year
Multiple Sclerosis
Primary: Expanded Disability Status Scale (EDSS) Improvement — 3.4; 3.3; 2.5; 3.7 units on a scale
Multiple Sclerosis, Primary Progressive · Multiple Sclerosis, Secondary Progressive
Primary: Covariate-adjusted Mean Rate of Change in Brain Atrophy Over 96 Weeks as Measured by Brain Parenchymal Fraction (BPF). — -0.00168; -0.00392 ratio — p=0.04
Multiple Sclerosis
Primary: Rate of Change in Brain Parenchymal Fraction — 0.107; -0.355 percentage of change in brain volume — p=0.346
Multiple Sclerosis
Primary: Expanded Disability Status Scale (EDSS) Plus — 17; 17 Participants — p=1.0
Multiple Sclerosis
Primary: Change in Mobility: Timed 25 Foot Walk — -0.39; -0.30 feet per second — p=0.51
Multiple Sclerosis, Chronic Progressive
Primary: Brain Atrophy by MRI — -0.4; -1.3 whole brain percent volume change
Secondary Progressive Multiple Sclerosis
Primary: Percentage Change in Whole Brain Volume — 0.288; 0.584 percentage of brain volumen change — p=0.003
Multiple Sclerosis
Primary: Percentage of Participants With Infusion-related Reaction (IRR) Treated With 600 mg IV Ocrelizumab — 0 Percentage of Participants
Secondary Progressive Multiple Sclerosis · Primary Progressive Multiple Sclerosis
Primary: Number of Participants Classified as Upper Limb Responders on the 9 Hole Peg Test (9HPT) — 4; 3; 58; 59 Participants
Relapsing-remitting Multiple Sclerosis · RRMS
Primary: Summary of Raw Number of Cumulative Combined Unique Active Lesions in Patients With Relapsing Remitting Multiple Sclerosis by Visit and Treatment — 2.4; 3.2; 3.9; 5.4…
Multiple System Atrophy
Primary: Change of Score in Motor Examination (ME) of the Unified MSA Rating Scale (UMSARS-ME) From V1 to V7. — 5.66; 6.60 score on a scale — p=0.51
Logopenic Variant Primary Progressive Aphasia · Non-fluent Variant Primary Progressive Aphasia · Semantic Variant Primary Progressive Aphasia
Primary: Changes in Language as Measured Through the Boston Naming Test (BNT) — 1.8; 2.5; 0.063; 0.5 Items
Progressive Supranuclear Palsy · Dementia With Lewy Bodies · Multiple System Atrophy
Primary: Change in Patient Quality of Life as Measured by the EuroQol 5-D (EQ-5D) Scale Between Baseline (Visit 1) and 1 Year (Visit 4) — 1; 0.5; 0.5; 0 units on a scale — p=0.59
Multiple Sclerosis
Primary: The Brief Repeatable Battery of Rao — 42.09; 35.5 Correct words — p=0.028
Multiple Sclerosis, Chronic Progressive
Primary: Number of Participants With Treatment-emergent Adverse Events — 18 Participants
Multiple System Atrophy
Primary: Number of Adverse Events up to Six Months Post-treatment — 43; 0 Adverse events
Primary Progressive Multiple Sclerosis
Primary: Percent Brain Volume Change (PBVC) From Baseline to Week 48 Using a Repeated Measures ANCOVA Model — -0.454; -0.438 percentage change from baseline — p=0.903
Multiple Sclerosis · Demyelinating Disorder · Autoimmune Diseases
Primary: Kinematics — 15.5; 10 degrees
Primary Progressive Aphasia · MCI · FTD
Primary: Absolute Percent Change in Written Naming (Trained Items) — 39.4; 28.4; 33.1; 20.0 absolute percent change
Secondary Progressive Multiple Sclerosis
Primary: Percentage of Participants With 3-month Confirmed Disability Progression (CDP) Events as Measured by the Expanded Disability Status Scale (EDSS) — 26.3; 31.7 Percentage…
Relapsing-remitting Multiple Sclerosis · Secondary Progressive Multiple Sclerosis
Primary: Proportion of Research Cohort Subjects Referred Into a Clinical Trial or Offered Treatment With an Appropriate Second-line Therapy. — 178 Participants
Relapsing Multiple Sclerorsis · Multiple Sclerosis, Primary Progressive
Primary: Change in Levels of NfL (Neurofilament Light) in CSF From Treatment Baseline to Post-Treatment With Ocrelizumab — -1232.97; -1169.13; -1008.13; -931.83 pg/mL
Multiple Sclerosis
Primary: Expanded Disability Status Score — 2.9; 2.6 score on a scale
Multiple Sclerosis
Primary: Treatment Satisfaction Questionnaire for Medication (TSQM) Version 1.4 - Assessment of Global Satisfaction Subscale Score With Teriflunomide Treatment at Week 48 — 68.17…